Concepedia

Ray McDermott

RM

Statistics

Publications

148

Citations

25K

H-Index

57

Active since

1991

Affiliations

St. Vincent's University Hospital(Current)

Cancer Trials Ireland

Tallaght University Hospital

Institut Gustave Roussy

Merck & Co., Inc., Rahway, NJ, USA (United States)

Ray McDermott is an author at St. Vincent's University Hospital specializing in medicine, oncology, and cancer therapeutics.

ORCID

Top concepts

Publications per year

1991–2025

148

Publications

148

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini, Elizabeth R. Plimack, V.P. Stus et al. · New England Journal of Medicine · 2019 · 3.3K citations · Full text

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

Michael J. Overman, Ray McDermott, Joseph L. Leach et al. · The Lancet Oncology · 2017 · 2.7K citations · Full text

, , +8

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong et al. · Journal of Clinical Oncology · 2018 · 2K citations · Full text

, , +18

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Ian D. Davis, Andrew Martin, Martin R. Stockler et al. · New England Journal of Medicine · 2019 · 1.5K citations

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · The Lancet · 2018 · 1.3K citations · Full text

, , +7

1–5 of 148